Summary NAD(P)H:quinone oxidoreductase (NQO1, EC 1.6.99.2) is an obligate two-electron reductase that can either bioactivate or detoxify quinones and has been proposed to play an important role in chemoprevention. We have previously characterized a homozygous point mutation in the BE human colon carcinoma cell line that leads to a loss of NOO1 activity. Sequence analysis showed that this mutation was at position 609 of the NQO1 cDNA, conferring a proline to serine substitution at position 187 of the NQO1 enzyme. Using polymerase chain reaction (PCR) analysis, we have found that the H596 human non-small-cell lung cancer (NSCLC) cell line has elevated NQO1 mRNA, but no detectable enzyme activity. Sequencing of the coding region of NQO1 from the H596 cells showed the presence of the identical homozygous point mutation present in the BE cell line. Expression and purification of recombinant wild-type and mutant protein from E. coli showed that mutant protein could be detected using immunoblot analysis and had 2% of the enzymatic activity of the wild-type protein. PCR and Northern blot analysis showed moderate to low levels of expression of the correctly sized transcript in the mutant cells. Immunoblot analysis also revealed that recombinant mutant protein was immunoreactive; however, the mutant protein was not detected in the cytosol of either BE or H596 cells, suggesting that the mutant proteins were either not translated or were rapidly degraded. The absence of any detectable, active protein, therefore, appears to be responsible for the lack of NQO1 activity in cells homozygous for the mutation. A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis for the mutation at position 609 conducted on 90 human lung tissue samples (45 matched sets of tumour and uninvolved tissue) revealed a 7% incidence of individuals homozygous for the mutation, and 42% heterozygous for the mutation. These data suggest that the mutation at position 609 represents a polymorphism in an important xenobiotic metabolizing enzyme, which has implications for cancer therapy, chemoprevention and chemoprotection.
NAD(P)H:quinone oxidoreductase (NQO1) is an obligate twoor four-electron reductase that plays a role in protection against natural and xenobiotic quinones. Compounds such as butylated hydroxyanisole, butylated hydroxytoluene, Oltipraz and extracts of cruciferous vegetables, such as green onions and broccoli, are potent inducers of NQO1 (Wattenberg, 1985; Prochaska et al, 1992; Zhang et al, 1992; Enger et al, 1994) . These chemicals have been shown to protect against toxicity, mutagenesis or carcinogenesis, suggesting that induction of NQO I may play a major role in cytoprotection and chemoprevention (Wattenberg, 1985) . Paradoxically, NQOI can also activate anti-tumour quinones, such as mitomycin C, E09, streptonigrin and diaziquone, via the production of redox labile hydroquinones or reactive alkylating agents generated by rearrangement after reduction by the enzyme Walton and Workman, 1990; Gibson et al, 1992 Gibson et al, , 1994 Ross et al, 1993; Beall et al, 1994) . NQO1 is expressed in many human tissues, and NQOI levels have been shown to be elevated in lung, colon, liver and breast cancer tissues compared with uninvolved tissue from the same origin (Schlager and Powis, 1990; Malkinson et al, 1992) .
In 1980, Edwards et al, showed that NQOl was lacking in 4% of a British population (Edwards et al, 1980) . We characterized a point mutation in the BE colon carcinoma cell line that led to a loss of enzymatic activity consistent with the absence of enzymatic activity observed in the previous studies (Traver et al, 1992) . Sequencing analysis revealed a homozygous C to T point mutation at position 609 of the NQO1 cDNA, which conferred a proline to serine substitution at position 187 of the NQO1 protein. This was the first mutation identified in the coding region of NQOl, and we suggested that it was responsible for the lack of NQO1 activity in these cells. Although BE cells have recently been reported to be heterozygous for the C to T mutation at position 609 by Kuehl et al (1995) , their status as homozygous mutants has been confirmed by collaborative studies in the two laboratories involved . NQO1 has also been shown to be absent in both normal and cancerous tissues of three out of 23 (13%) renal carcinoma patients, and these three individuals were all homozygous for the mutant allele (Eickelmann et al, 1994a,b) . Marshall et al characterized a lack of NQO1 activity in fibroblasts form a cancer-prone family and made the suggestion that deficient NQO1 activity may predispose to cancer (Marshall et al, 1991a,b) . Rosvold et al (1995a) have subsequently used single-strand conformation polymorphism (SSCP) analysis to show that the mutant allele occurred with a frequency of 0.13 in a reference population. The data *Present address: Research Group, Cancer Research Division, Pfizer Inc., Groton, CT, USA suggest that the mutation at position 609 represents a polymorphism in a drug-metabolizing enzyme. The functional significance of this polymorphism, as well as its occurrence in the population as a homozygous or heterozygous trait, however, remains unclear.
Recently, we found that the H596 non-small-cell lung cancer (NSCLC) cell line had moderate levels of NQOI gene expression but no detectable enzymatic activity (Traver et al, 1995) . In this manuscript, we show the presence of the identical C to T point mutation present in the BE cells in the coding region of H596 cells. Using PCR, Northern and immunoblot analysis, we have examined the effects of the homozygous C to T point mutation on the production of NQOI. Additionally, we have screened 90 human lung samples from both normal and paired tumour tissue to elucidate the incidence of this mutation at position 609 more clearly. These findings have implications for chemoprevention and for the treatment of cancers with drugs that require bioreductive activation by NQO1.
MATERIALS AND METHODS Cell lines
Cells were grown as monolayers at 37°C in minimum essential medium (Gibco, BRL) supplemented with 10% fetal bovine serum (FBS; Gibco, BRL), penicillin (10 units ml-'), streptomycin (10 units ml-'), L-glutamine (2 mM) and non-essential amino acids (0.1 M).
Analysis of N01 enzymatic activity
Cells were grown to 80% confluence before being washed with Hanks' balanced salt solution and scraped into ice-cold buffer [25 mm ) and 125 mm sucrose]. A cell sonicate was then made for each cancer cell line by sonicating the cell suspension for 30 s on ice. NQO1 activity of the cell sonicates was then assayed according to Ermster (1967) , as modified by Benson et al (1980) . Reactions (0.5 ml) were performed at 25°C in the presence and absence of 0.02 mm dicoumarol in a buffer containing 25 mM Tris-HCl (pH 7.4), 0.7 mg ml-' bovine serum albumin (BSA), 0.2 mm NADH and 0.04 mm dichlorophenolindophenol (DCPIP). NQO1 activity was measured as the dicoumarol-sensitive reduction of DCPIP (e 21 000 M-l cm-') measured by the decrease in absorbance at 600 nm in a Shimadzu UV16OU spectrophotometer. Protein content in the cell sonicates was assayed by the method of Bradford (1976) .
RNA extraction and cDNA synthesis RNA was extracted fiom cell cultures using the method described by Peppel and Baglioni (1990) . All cells were in the exponential phase of the growth curve at the time of RNA extraction. RNA pellets were dissolved in DEPC-treated water and immediately reverse transcribed. The reverse transcription reaction contained 20 gl of 5 x reverse transcription buffer (Gibco BRL), 10 ,ul of dNTPs (10 mm, Pharmacia), 2.5 p1 of RNAasin (40 U pl-', Promega), 0.5 gl of random hexamers (18 U ml-', Pharmacia), 10 pl of dithiothreitol (0.1 M, Gibco BRL), 400 U of MMLV reverse transcriptase (Gibco BRL) and 55 gl of RNA(7.5-10 ,ug). The reaction was incubated at 37°C for 1 h followed by heating to 95°C for S min. The quantity of RNA extracted was determined by absorbance readings at 260-280 nm and reference to a calibration curve generated using yeast tRNA (Sigma).
Quantitation of NQ01 expression by PCR NQO1 expression was determined using a semi-quantitative reverse transcription-PCR technique, details of which are described elsewhere (Phillips et al, 1993 Sequencing and cloning of the NQ01 coding region
The coding region from the wild-type H460 cells and the mutant BE and H596 cells was sequenced by amplification of aliquots of cDNA from these cell lines. The resulting double-stranded DNA fragments were then denatured and sequenced with Sequenase II (USB). The NQO1 coding region from the wild-type H460 cells and the mutant BE and H596 cells was amplified using an antisense primer that included a 5'HindIII cut site and a sense primer spanning the naturally occurring NcoI cut site immediately 5' to the start codon. The resulting PCR product was then cut with HindIII and NcoI and ligated into pKK233-2. The resulting vector was transformed into JM109 E. coli for amplification and purification.
Purification of recombinant NQ01 E. coli expressing either wild-type or mutant NQO1 proteins were grown to log phase in the presence of 2 mm isopropyl-o-Dthiogalactopyranside. A 50-g pellet of these cells was then sonicated on ice in 25 mM Tris HCL, pH 7.4, containing 125 mM sucrose, and centrifuged at 100 000 g for 90 min. The resulting supematant was examined for NQO1 protein expression by immunoblot analysis (see below). No NQOl protein was detected in untransformed E. coli; however, NQO1 protein was detected in E. coli transformed with the coding region from both wild-type (H460) and mutant (BE, H596) cells. Wild-type and mutant NQO1 proteins were purified from the supernatant by Cibacron blue affinity chromatography as described previously (Sharkis and Swenson, 1989) . Purified wild-type and mutant NQO1 proteins were both resolved as a single band on 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) with a molecular mass of 30 kDa. Purified wild-type and mutant NQO1 proteins had a FAD to protein monomer ratio of approximately 1:1 (Faeder and Siegel, 1973) . Enzyme activity of the purified recombinant proteins was assayed using dicoumarol-sensitive DCPIP reduction as described above.
Immunoblot analysis and N-terminal sequencing E. coli cytosols, H460, H596 and BE cell cytosols and purified wild-type and mutant NQO1 proteins were examined by immunoblot analysis for reactivity against a mouse monoclonal antibody (B771) raised against wild-type (H460) NQO1 in our laboratory or a polyclonal antibody (gift from Dr G Powis, University of Arizona, USA). The proteins were first separated by 12% SDS-PAGE and then transferred to nitrocellulose in 10 mm Tris, 192 mM glycine containing 20% methanol at 35 V for 14 h. Following transfer, the nitrocellulose was blocked with 1% BSA for 1 h and then 20 ml of B771 hybridoma tissue culture media was added for 1 h followed by a goat antimouse IgG-alkaline phosphatase conjugate (1:5000) for 30 min. Visualization was performed with BCIP/NBT. N-terminal sequencing was carried out on purified recombinant wild-type and mutant NQO1 proteins following 12% SDS-PAGE and transfer to PVDF membrane. N-terminal sequencing was performed at the Protein Sequencing Core Facility, University of Colorado Health Sciences Center. The N-terminal sequence for H460-and BE-derived NQO1 proteins was consistent with the previously published sequence for human liver NQO1 (Jaiswal et al, 1988) .
PCR-RFLP analysis of DNA samples for the mutation PCR products were generated using 1 gg of genomic DNA extracted from matched tumour and normal lung biopsies from lung cancer patients. These PCR products were examined for the presence of the mutation using an RFLP assay developed by Eickelmann et al (1994b) with the following modifications. The sense primer (5' TCCTCAGAGTGGCATTCTGC-3') and antisense primer (5'-TCTCCTCATCCTGTACCTCT-3') amplified a 211 -bp region, including the last seven bases of exon 5 and the first 204 bases of intron 6. Thermal cycling conditions were 
RESULTS
We compared NQO1 gene expression and enzymatic activity in a panel of small-cell lung cancer (SCLC) and NSCLC cell lines (Table 1 ). This analysis resulted in a good correlation (r = 0.97) between gene expression and enzymatic activity in these lung carcinoma cells. H596 NSCLC cells, however, fell notably outside this correlation with moderate NQOI gene expression, but almost no enzymatic activity. To determine whether this discrepancy was also caused by a mutation in the coding region of the NQOI gene, the cDNA from these cells was cloned and sequenced revealing the identical homozygous C to T point mutation (Figure 1 ) that we characterized as being responsible for the lack of NQO I activity in BE human colon carcinoma cells. We had previously reported in abstract form (Traver et al, 1995) that the H596 cells had an additional A to T point mutation at position 790 of the cDNA. After sequencing of the cDNA from H596 cells, it appears that this mutation was generated during PCR amplification and subcloning and is not present in native H596 cDNA.
Northern analysis of N01 transcripts
Northern analysis was used to confirm the presence and size of the NQO1 transcript in cell lines containing the mutation. The NQOI transcript has four polyadenylation sites in the 3' untranslated region (Jaiswal, 1991) . Three of these sites are used to produce transcripts 1.2 kb, 1.7 kb and 2.7 kb in size. Northern analysis revealed NQOI transcripts in BE and H596 cells, which were identical in size to the transcripts present in wild-type cells from the tissue of the same origin (Figure 2 ).
Immunoblot analysis of N01 proteins
Immunoblot analysis was used to verify the presence and size of the NQO1 proteins from E. coli and human cell lines expressing the mutant NQO1 genes. Figure 3 shows an immunoblot comparing NQOI proteins in cytosol or recombinant proteins purified from E. coli. Lane 1 contains the recombinant H460 wild-type protein purified from E. coli and lane 2 contains the cytosol from the H460 NSCLC cell line, which expresses the wild-type NQO1. Lane 3 contains cytosol from the H596 cells, which does not show any detectable NQO1 protein. Similarly, lane 4 contains the recombinant, mutant protein purified from E. coli expressing the coding region from the BE colon carcinoma cell line, which has the proline to serine substitution, and lane 5 contains cytosol from the BE cells. Again, the mutant NQO1 protein is absent in the cytosol from cells that are homozygous for the C to T point mutation at position 609. Identical data demonstrating an absence of NQO1 protein in H596 and BE cells have also been obtained using a polyclonal antibody to NQOl (data not shown).
Enzymatic activity of recombinant N01 proteins
In order to examine the activity of the mutant NQOI protein, the coding region of NQO1 from the H460 cells expressing the wildtype protein, as well as the coding region from the BE colon carcinoma cells, were expressed in E. coli and purified as described in Materials and methods. Purified recombinant NQOI from E. coli expressing the wild-type protein had a specific activity averaging 645 ,umol min-'mg-' protein. The 
Frequency of the C to T point mutation
To clarify the prevalence of the C to T point mutation at position 609 of the NQO 1 cDNA, a PCR-RFLP analysis was used to screen tumour and uninvolved tissue from 45 lung cancer patients ranging in age from 33 to 81 years. Normal tissue samples from these patients included uninvolved lung tissue or blood samples from these individuals. Table 2 shows the results of this screening. A total of 51% of the lung cancer samples were homozygous for the wild-type protein, while 42% were heterozygous for the mutation and 7% were homozygous for the mutation.
Histologically, the tumour tissues examined were composed of squamous cell cancers, adenocarcinomas, small-cell and large-cell lung cancers, bronchioalveolar cancers, a carcinoid tumour and an adenosquamous cancer. Tumour samples homozygous for the mutation included a carcinoid tumour and two adenocarcinomas with bronchioalveolar components. Tumour samples heterozygous for the mutant allele were composed primarily of squamous cell cancers (45%) and adenocarcinomas (40%) with one small-cell lung cancer and one adenosquamous cancer. Tumour samples homozygous for the wild-type allele were composed of 48% squamous cell cancers, 28% adenocarcinomas, 12% small-cell lung cancers, 8% bronchioalveolar cancers and one large-cell lung cancer.
DISCUSSION
The enzymatic activities of the recombinant proteins presented here show that the purified recombinant NQOl protein carrying the proline to serine substitution at amino acid 187 has only 2% of the enzymatic activity of the wild-type enzyme. In our previous work, we speculated that the proline to serine substitution in the NQOI enzyme could adversely affect the pyridine nucleotidebinding site of the enzyme. Subsequently, Ma et al (1992) demonstrated that the glycine residue at position 150, the serine residue at position 151 and the tyrosine residue at position 155 of the NQOI protein were essential for pyridine nucleotide binding, and that the tyrosine at position 128 was important for dicoumarol binding. This suggests that the pyridine nucleotide-binding site may be unaffected by the loss of the proline residue at position 187. The crystal structure of the rat enzyme published recently by Li et al (1995) has defined the binding sites for both pyridine nucleotide and quinone substrates. This work indicates extensive overlap between these binding sites and confirms that both binding sites are not directly affected by the proline substitution at position 187. The crystal structure indicates that the proline at position 187 is located at the end of a beta sheet and is adjacent to an exposed loop (Li et al, 1995) . A mutation at this position may, therefore, cause structural alterations in this area and compromise loop stability. The effects of the proline to serine substitution at position 187 on protein structure are, therefore, unclear at present but obviously have profound consequences on the activity of NQO1. It is important to stress that, although a heterozygous C to T mutation at position 609 may be associated with widely differing NQO1 activities (Kuehl et al, 1995) , a homozygous C to T mutation results in a lack of NQOl protein and activity.
The human NQO1 gene is composed of six exons separated by five introns and is located on chromosome 16. The last exon has four polyadenylation sites, three of which are used, giving rise to 1.2 kb, 1.7 kb and 2.7 kb transcripts (Jaiswal, 1991) . PCR analysis showed that the NQOl gene is transcribed at moderate levels, and our Northern analysis showed transcripts of the correct size in cells that are homozygous or heterozygous for the mutation. This suggests that the NQO I gene is successfully transcribed and appropriately spliced in cells containing the mutation.
Immunoblot analysis of recombinant and cytosolic NQOl proteins showed that the recombinant enzyme containing the C to T mutation at position 609 can be expressed in E. coli, purified and detected using immunoblots. Our data show that the mutant protein is of the correct molecular weight but almost completely dysfunctional as indicated by activity assays. In addition to the recombinant wild-type protein, the NQO1 enzyme is detectable on immunoblot analysis in the cytosol of the H460 cells, which express the functional NQO1 gene. The mutant enzyme expressed in E. coli is also detectable by immunoblot analysis; however, the cytosol from both H596 and BE cells, which carry the homozygous C to T mutation, did not contain any detectable NQOl (Rosvold et al, 1995b; Kolesar et al, 1995) . The data we present here show a frequency of 7% of both tumour and normal tissue samples homozygous for the mutation, while 42% of the samples were heterozygous for the mutation. The presence of the mutation in matched lung and blood samples suggests that, in these patients, the mutation is neither tissue nor tumour specific, but represents a true polymorphism. Polymorphisms have been established in numerous phase I and phase II metabolic enzymes (Gonzalez and Idle, 1994) . Examples include many members of the cytochrome P450 family of metabolic enzymes, as well as oxidases, reductases and esterases. Polymorphisms in phase II metabolic enzymes include sulpho, acetyl, methyl and glutathione transferases. These polymorphisms are associated with significant alterations in response and susceptibility to xenobiotics (Caporaso et al, 1991) . We have shown that NQO I is important in protection against benzene-derived quinones Ganousis et al, 1992) . In very recent work, we have demonstrated that workers with the NQOI polymorphism are at increased risk of benzene-induced decreases in white blood cell count relative to matched controls (Rothman etal, 1996) .
A polymorphism leading to a lack of NQO1 activity is of special significance in that the enzyme acts as a protective measure against oxidative damage produced by a wide range of naturally occurring and xenobiotic quinones, which undergo redox cycling subsequent to two-electron reduction by NQOI (Prochaska et al, 1992; Zhang et al, 1992; Enger et al, 1994) . A lack of NQOI may have implications for both chemoprotection and chemoprevention. Indeed, the potential benefit of chemopreventive agents, which act through the induction of NQO1, could be significantly decreased in populations homozygous for this mutation. Additionally, the presence of this polymorphism presents significant problems in the exploitation of the elevated NQOI activity of certain tumours by administering anti-tumour quinones, which require bioreductive activation. In an attempt to predict the clinical response of tumours to these drugs, it has been suggested that NQO I expression in tumour samples could be evaluated by PCR before drug treatment. The presence of this mutation would lead to tumour types that are unresponsive to these drugs, despite apparent elevated NQO1 gene expression as detected by PCR. As such, it will be necessary to confirm the absence of the mutation at position 609 using PCR-RFLP analysis or, more importantly, the presence of NQOI activity in these samples for studies of this kind to be successful.
In summary, we have characterized a proline to serine mutation in NQOI, which results in a complete loss of enzyme activity. Although 
